Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients

INTRODUCTION: The EXPEDITION-8 clinical trial has demonstrated that treatment-naïve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1–6 can achieve a 98% intent-to-treat sustained virologic response rate 12 weeks post-treatment with an 8-week glecaprevir/pibrentasvir (G/P) regimen. Furt...

Descripción completa

Detalles Bibliográficos
Autores principales: Reau, Nancy, Cheng, Wei-Han, Shao, Qiujun, Marx, Steven E., Brooks, Hannah, Martinez, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390440/
https://www.ncbi.nlm.nih.gov/pubmed/37329414
http://dx.doi.org/10.1007/s40121-023-00823-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390440/
https://www.ncbi.nlm.nih.gov/pubmed/37329414
http://dx.doi.org/10.1007/s40121-023-00823-z

Ejemplares similares